Complement activation by the artificial surface of cardiopulmonary bypass is a persistent clinical problem

Joel David Bierer; Roger Stanzel; Mark Henderson; Tony El-Rabahi; John Sapp; Pantelis Andreou; Jean S. Marshall; David Conrad; David Horne

doi:10.1038/s41598-025-11157-w

journal article Open Access Jul 29, 2025

Complement activation by the artificial surface of cardiopulmonary bypass is a persistent clinical problem

Joel David Bierer Roger Stanzel Mark Henderson Tony El-Rabahi John Sapp

Pantelis Andreou Jean S. Marshall David Conrad David Horne

Scientific Reports Vol. 15 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41598-025-11157-w

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785–797 (2010). 10.1038/ni.1923

[2]

Ricklin, D. & Lambris, J. D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831–3838 (2013). 10.4049/jimmunol.1203487

[3]

Oikonomopoulou, K., Ricklin, D., Ward, P. A. & Lambris, J. D. Interactions between coagulation and complement—Their role in inflammation. Semin. Immunopathol. 34, 151–165 (2012). 10.1007/s00281-011-0280-x

[4]

Nilsson, B., Ekdahl, K. N., Mollnes, T. E. & Lambris, J. D. The role of complement in biomaterial-induced inflammation. Mol. Immunol. 44, 82–94 (2007). 10.1016/j.molimm.2006.06.020

[5]

Skinner, S. C. et al. Hemodialysis-related complement and contact pathway activation and cardiovascular risk: a narrative review. Kidney Med. 3, 607–618 (2021). 10.1016/j.xkme.2021.04.006

[6]

Markiewski, M. M. & Lambris, J. D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171, 715–727 (2007). 10.2353/ajpath.2007.070166

[7]

Parker, D. Changes in serum complement and the immunoglobulin after cardiopulmonary bypass. Br. J. Surg. 59, 910–911 (1972).

[8]

Kirklin, J. K. et al. Complement and the damaging effects of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 86, 845–857 (1983). 10.1016/s0022-5223(19)39061-0

[9]

Bronicki, R. A. & Hall, M. Cardiopulmonary bypass-induced inflammatory response: Pathophysiology and treatment. Ped. Crit. Care Med. 17, S272–S278 (2016). 10.1097/pcc.0000000000000759

[10]

Paparella, D., Yau, T. M. & Young, E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur. J. Cardiothoracic. Surg. 21, 232–244 (2002). 10.1016/s1010-7940(01)01099-5

[11]

Shen, I., Giacomuzzi, C. & Ungerleider, R. M. Current strategies for optimizing the use of cardiopulmonary bypass in neonates and infants. Ann. Thorac. Surg. 75, S729–S734 (2003). 10.1016/s0003-4975(02)04697-0

[12]

Bierer, J., Stanzel, R., Henderson, M., Sett, S. & Horne, D. Ultrafiltration in pediatric cardiac surgery review. World J. Pediatr. Congenit. Heart Surg. 10, 778–788 (2019). 10.1177/2150135119870176

[13]

Bierer, J. et al. Sanguineous cardiopulmonary bypass prime accelerates the inflammatory response during pediatric cardiac surgery. Perfusion 0, 1–11 (2024).

[14]

Osthaus, W. A., Sievers, J., Breymann, T. & Suempelmann, R. Bicarbonate buffered ultrafiltration leads to a physiologic priming solution in pediatric cardiac surgery. Interact. Cardiovasc. Thorac. Surg. 7, 969–972 (2008). 10.1510/icvts.2008.179333

[15]

Osthaus, W. A. et al. Bicarbonate-buffered ultrafiltration during pediatric cardiac surgery prevents electrolyte and acid-base balance disturbances. Perfusion 24, 19–25 (2009). 10.1177/0267659109106728

[16]

Bierer, J., Henderson, M., Stanzel, R., Sett, S. & Horne, D. Subzero balance - simple modified ultrafiltration (SBUF-SMUF) technique for pediatric cardiopulmonary bypass. Perfusion 37, 785–788 (2022). 10.1177/02676591211027788

[17]

Bierer, J. et al. Unmasking culprits: novel analysis identifies complement factors as potential therapeutic targets to mitigate inflammation during children’s heart surgery. Eur. J. Med. Res. 29, 1–13 (2024). 10.1186/s40001-024-02156-0

[18]

Willems, E. et al. Biosynthetic homeostasis and resilience of the complement system in health and infectious disease. EBioMedicine 45, 303–313 (2019). 10.1016/j.ebiom.2019.06.008

[19]

Sonntag, J., Stiller, B., Walka, M. M. & Maier, R. F. Anaphylatoxins in fresh-frozen plasma. Transfusion 37, 798–803 (1997). 10.1046/j.1537-2995.1997.37897424401.x

[20]

Burnouf, T., Kappelsberger, C., Frank, K. & Burkhardt, T. Protein composition and activation markers in plasma collected by three apheresis procedures. Transfusion 43, 1223–1230 (2003). 10.1046/j.1537-2995.2003.00505.x

[21]

Norda, R. et al. Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma. Vox Sang. 102, 125–133 (2012). 10.1111/j.1423-0410.2011.01522.x

[22]

Kozik, D. J. & Tweddell, J. S. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann. Thorac. Surg. 81, S2347–S2354 (2006). 10.1016/j.athoracsur.2006.02.073

[23]

Bierer, J. et al. Novel inflammatory mediator profile observed during pediatric heart surgery with cardiopulmonary bypass and continuous ultrafiltration. J. Transl. Med. 21, 1–12 (2023). 10.1186/s12967-023-04255-8

[24]

Mangoush, O. et al. Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes. Eur. J. Cardiothor. Surg. 31, 1058–1069 (2007). 10.1016/j.ejcts.2007.01.029

[25]

Tamim, M., Demircin, M., Guvener, M., Peker, O. & Yilmaz, M. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass. Panminerva Med. 193–198 (1999).

[26]

Ricklin, D., Reis, E. S., Mastellos, D. C., Gros, P. & Lambris, J. D. Complement component C3—The “Swiss Army Knife” of innate immunity and host defense. Immunol. Rev. 274, 33–58 (2016). 10.1111/imr.12500

[27]

Campbell, W. D., Lazoura, E., Okada, N. & Okada, H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol. Immunol. 46, 131–134 (2002). 10.1111/j.1348-0421.2002.tb02669.x

[28]

Monk, P. N., Scola, A. M., Madala, P. & Fairlie, D. P. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 152, 429–448 (2007). 10.1038/sj.bjp.0707332

[29]

Colvin, M. M. et al. Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management: A scientific statement from the American Heart Association: Endorsed by the international society for heart and lung transplantation. Circulation 131, 1608–1639 (2015). 10.1161/cir.0000000000000093

[30]

Cerier, E. et al. Temporal correlation between postreperfusion complement deposition and severe primary graft dysfunction in lung allografts. Am. J. Transplant. 24, 577–590 (2024). 10.1016/j.ajt.2023.11.006

[31]

Coutance, G. et al. Intermediate-term outcomes of complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. J. Heart Lung Transplant. 42, 1464–1468 (2023). 10.1016/j.healun.2023.05.005

[32]

Grafals, M. & Thurman, J. M. The role of complement in organ transplantation. Front. Immunol. 10, 1–10 (2019). 10.3389/fimmu.2019.02380

[33]

Chang, D. & Kobashigawa, J. Cardiac allograft immune activation: Current perspectives. Transpl. Res. Risk. Manag. 7, 13–22 (2014).

[34]

Stepniewska, J. et al. The activation of complement system in different types of renal replacement therapy. J. Physiol. Pharmacol. 71, 275–281 (2020).

[35]

Ricklin, D. Complement-targeted therapeutics: Are we there yet, or just getting started?. Eur. J. Immunol. 54, 1–15 (2024). 10.1002/eji.202350816

[36]

Ricklin, D. & Lambris, J. D. Therapeutic control of complement activation at the level of the central component C3. Immunobiology 221, 740–746 (2016). 10.1016/j.imbio.2015.06.012

[37]

Bierer, J. et al. High-exchange ULTrafiltration to enhance recovery after paediatric cardiac surgery (ULTRA): study protocol for a Canadian double-blinded randomised controlled trial. BMJ Open 14, 1–6 (2024). 10.1136/bmjopen-2023-080597

[38]

Bergseth, G. et al. An international serum standard for application in assays to detect human complement activation products. Mol. Immunol. 56, 232–239 (2013). 10.1016/j.molimm.2013.05.221

[39]

Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest package: tests in linear mixed effects models. J. Stat. Softw. 82, 1–26 (2017). 10.18637/jss.v082.i13

[40]

Nakagawa, S. & Schielzeth, H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol. Evol. 4, 133–142 (2013). 10.1111/j.2041-210x.2012.00261.x

Metrics

3

Citations

40

References

Details

Published: Jul 29, 2025
Vol/Issue: 15(1)
License: View

Authors

Funding

Canadian Institutes of Health Research Award: Doctoral Research Award (#181479)

Research Nova Scotia Award: Doctoral Award

Nova Scotia Department of Health and Wellness Award: Clinician Investigator Program

IWK Health Centre,Canada Award: Lab Medical Group Trust Fund

Dalhousie University Award: Department of Surgery Grant

Cite This Article

Joel David Bierer, Roger Stanzel, Mark Henderson, et al. (2025). Complement activation by the artificial surface of cardiopulmonary bypass is a persistent clinical problem. Scientific Reports, 15(1). https://doi.org/10.1038/s41598-025-11157-w

Complement activation by the artificial surface of cardiopulmonary bypass is a persistent clinical problem

You May Also Like